戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ch a diagnosis and may predict the risk of a systemic reaction.
2 of the 21 subjects who received stings had a systemic reaction.
3 anut-allergic subjects suffering from severe systemic reactions.
4               There were no serious local or systemic reactions.
5  reported a higher incidence of food-induced systemic reactions.
6 ated with mostly mild and transient local or systemic reactions.
7 rointestinal AEs, and AR predicted increased systemic reactions.
8   Ultrarush initiation increases the risk of systemic reactions.
9 dministration intervals, but it caused fewer systemic reactions.
10 es include nuisance biting and cutaneous and systemic reactions.
11 een reported, including cutaneous and rarely systemic reactions.
12 that are associated with a high incidence of systemic reactions.
13 stration is associated with a risk of severe systemic reactions.
14 atients (8.3% of all patients) experienced 6 systemic reactions (0.15% of doses).
15           Anaphylactic shock (76.6%), severe systemic reactions (10.5%), acute laryngeal edema (9%),
16 form of meat allergy characterized by severe systemic reactions 3-7 h after consumption of red meat.
17 ll tolerated, with occasional, usually mild, systemic reactions (abdominal pain, arthralgia, and diar
18          However, rates of local induration, systemic reactions, adverse events (AEs), and SAEs were
19                                    Local and systemic reactions after vaccination with LC16m8 were si
20 blet (SLIT-tablet) treatment, such as severe systemic reactions and asthma-related events.
21                                     However, systemic reactions and intolerable gastrointestinal AEs
22 ll-tolerated with only grade 1 to 2 local or systemic reactions and no treatment-limiting adverse eve
23    Approximately 42% of subjects experienced systemic reactions, and 49% experienced gastrointestinal
24 se showed promising efficacy, small risk for systemic reactions, and immunomodulatory changes in this
25 avenous immunoglobulin (IGIV), induces fewer systemic reactions, and may be self-infused.
26   Vaccine administration induced no local or systemic reactions, and no laboratory abnormalities were
27              A 51-year-old woman experienced systemic reactions beginning 10 days after cadaveric ren
28  with no significant differences in local or systemic reactions between groups.
29 se 4 was associated with increased local and systemic reactions, but the overall safety profile of a
30  all patients suggesting a radiation-induced systemic reaction; (c) changes in DTPA t 1/2 values were
31 (pain, erythema, induration, and warmth) and systemic reactions (chills, arthralgias, and myalgias) i
32 me was the occurrence of 1 or more objective systemic reactions during venom immunotherapy initiation
33          Treatment options for cutaneous and systemic reactions from bed bug bites have not been eval
34 p large local swelling or strictly cutaneous systemic reactions generally do not require immunotherap
35  frequently reported adverse events included systemic reactions (Group 1: 21% of patients, Group 2: 3
36 ed and who had a history of mild (cutaneous) systemic reaction (i.e., one with only cutaneous manifes
37   We sought to investigate the occurrence of systemic reactions in children with isolated sensitizati
38 er incidence of mild, self-limited local and systemic reactions in the vaccine group, but only during
39 well tolerated, with no significant local or systemic reactions in the women and no adverse outcomes
40 om immunotherapy may reduce the incidence of systemic reactions in those with a history of venom-trig
41                                              Systemic reactions included mild to moderate malaise and
42 nd in untreated patients with a history of a systemic reaction involving at least two different organ
43 as associated with mild-to-moderate local or systemic reactions lasting a median of three days.
44                       Local, mild, or severe systemic reactions may occur already after the first con
45 s (aP) vaccines has considerably reduced the systemic reactions observed with diphtheria-tetanus toxo
46                                              Systemic reactions occurred less frequently in patients
47                                     Local or systemic reactions occurred, respectively, in 40 (78%) a
48                                           No systemic reactions occurred.
49  The acute-phase response (APR) represents a systemic reaction of the organism to multiple nonspecifi
50 eater number of moderate or severe local and systemic reactions (of 16 participants, 4 had local reac
51   There was no pattern of vaccine-associated systemic reactions or clinically significant laboratory
52 1.0 kUA /l conferred a 97% probability for a systemic reaction (P = 0.0002).
53 sociated with a higher frequency of local or systemic reactions (P = 0.001, both).
54 ensitization and region on the occurrence of systemic reactions (P = 0.0185 and P = 0.0436, respectiv
55 nts of the higher dose had greater local and systemic reactions (P<.001).
56 , 7 had local reactions [P < 0.01] and 0 had systemic reactions [P < 0.001]).
57 ntrast administration can be associated with systemic reactions, renal disease, and thyroid dysfuncti
58 he association between sBT levels and severe systemic reactions (SR).
59             Outside clinical trials, data on systemic reactions (SRs) due to allergen immunotherapy (
60  fact stimulate more robust inflammatory and systemic reactions than RF at liver ablation, the author
61 rticipants, 4 had local reactions and 13 had systemic reactions) than did vaccine formulated with MF5
62 errulatus-envenomed victims exhibit local or systemic reaction that culminates in pulmonary oedema, p
63                              Trauma evokes a systemic reaction that includes an acute, non-specific,
64                    Four subjects had adverse systemic reactions that may have resulted from the inten
65 against GVHD, vaccination elicited local and systemic reactions that were qualitatively similar to th
66   There is evidence that the severity of the systemic reaction to infection (severe sepsis) is strong
67 d food challenge, 1 boy with a previous mild systemic reaction to peanut experienced lip swelling, st
68 ldren leads to a significantly lower risk of systemic reaction to stings even 10 to 20 years after tr
69 espiratory symptoms but inversely related to systemic reactions to food.
70 sp venom, and 32 controls without history of systemic reactions to Hymenoptera stings and no sIgE to
71 re considered to be a risk factor for severe systemic reactions to hymenoptera stings.
72  known to occur in a subset of patients with systemic reactions to Hymenoptera stings.
73 tosis and/or elevated sBT tryptase level and systemic reactions to hymenoptera venoms were analyzed f
74 ificantly associated with the development of systemic reactions to peanut.
75                                 No severe or systemic reactions to vaccination occurred, and five ser
76     If the child had a documented history of systemic reactions up to grade I anaphylaxis, double-bli
77 plasma tryptase and EDN, and the severity of systemic reactions was correlated with levels of tryptas
78                                              Systemic reactions were counted to evaluate safety.
79 ccine immunogenicity, and rates of local and systemic reactions were determined.
80                                    Local and systemic reactions were generally mild and, except for p
81                              The most common systemic reactions were headache, malaise, and myalgia.
82                                              Systemic reactions were less frequent with IGHy than wit
83 hough the overall reaction rate was similar, systemic reactions were more common during OIT than duri
84                                    Local and systemic reactions were more frequent after dose 4.
85                                    Objective systemic reactions were more likely during ultrarush ini
86               Although no acute cutaneous or systemic reactions were noted, endothelial cell activati
87                               Mild local and systemic reactions were noted.
88                                              Systemic reactions were rare, but local reactions (prima
89         Immunotherapy was well tolerated; no systemic reactions were reported.
90                       Stage 3 is the massive systemic reaction where cytokines turn destructive by co
91 frequency and severity of injection-site and systemic reactions within 28 days of each vaccination.
92  The primary safety endpoints were local and systemic reactions within 7 days after each injection, a
93      Solicited reports of injection-site and systemic reactions within 7 days after vaccination were
94 , at 4-7 days for postimmunization local and systemic reactions, within 28 days for adverse events, a

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。